Prime Medicine Inc
Company Profile
Business description
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Contact
60 First Street
CambridgeMA02141
USAT: +1 617 465-0013
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
146
Stocks News & Analysis
stocks
Beaten down real estate share receives legal blow
stocks
OpenAI joins the mega-AI lab IPO race, but timing is uncertain
stocks
What happens if Tesla and SpaceX merge?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,997.00 | 20.00 | 0.22% |
| CAC 40 | 8,200.80 | 38.97 | 0.48% |
| DAX 40 | 24,209.71 | 14.40 | 0.06% |
| Dow JONES (US) | 50,848.75 | 929.97 | 1.86% |
| FTSE 100 | 10,303.88 | 49.07 | 0.48% |
| HKSE | 24,691.96 | 442.67 | 1.83% |
| NASDAQ | 25,809.66 | 640.16 | 2.54% |
| Nikkei 225 | 66,442.95 | 2,225.68 | 3.47% |
| NZX 50 Index | 13,335.16 | 133.00 | 1.01% |
| S&P 500 | 7,394.30 | 127.31 | 1.75% |
| S&P/ASX 200 | 8,795.30 | 21.80 | 0.25% |
| SSE Composite Index | 4,057.88 | 70.87 | 1.78% |